News and Announcements
Shivom launch type II Diabetes study in India
- Published October 03, 2018 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
KEY TAKEAWAYS:
- Shivom launched their Type II Diabetes project in Andra pradesh, India.
- Shivom will use their Omix Platform to manage genomic data securely across the project.
- The company which combines blockchain, A.I., DNA sequencing & cryptography and is excited to announce it has opened offices in London.
Shivom have launched their Type II Diabetes project in Andra, Pradesh, India. This project will secure patients DNA data on to the OMIX platform and results will be released in 2019.
Patients for the study are being on boarded at SS Diagnostic Clinic and more will be selected in the next 6 months.
Shivom are excited to announce the development of the new Omix Platform, Alpha Release version.
The Alpha version is set to be launched in November this year.
The company, which is a Leading platform working on collaboration & integrity, allowing people to own, manage and monetize their data has expanded it’s global footprint and opened an office in London.
The London team will be led by Dr Natalie Pankova.
Upcoming Events for Shivom
- G4AGH: October 3rd – 5th 2018, Basel
- Malta Blockchain Summit: November 1st – 2nd 2018
- WebSummit: November 5th-8th 2018, Lisbon
- Healthcare Unblocked: November 9th 2018, London
About Shivom
Shivom combines blockchain, A.I., DNA sequencing & cryptography to enable secure and personalized medicine. The Shivom platform works on collaboration & integrity, allowing people to own, manage and monetize their data. By creating a web-marketplace, a network of genomic counsellors, and a not-for-profit drug research unit, Shivom will build a global healthcare ecosystem, reaching even low-income countries.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
